NASDAQ · OCX
Healthcare · Biotechnology
$3.20
Up+$0.47 (+17.22%)
Updated Oct 8, 2026, 5:19 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · OCX
1M range · 0 trading sessions · Daily adjusted prices
OCX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning OCX.
Company
Market Activity
Research & News
OCX research
Company profile and research snapshot.
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 21, 2025 | Lake Street | Buy | — |
| May 13, 2025 | Needham | Buy | — |
| Apr 8, 2025 | Needham | Buy | — |
| Mar 28, 2025 | Lake Street | Buy | — |
| Mar 26, 2025 | Stephens & Co. | Equal-Weight | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Oct 2, 2024
Oncocyte Corporation announced that its GraftAssure research assay has been adopted by two leading transplant university hospitals in the U.S. and Germany. The company has also submitted a plan for an IVD version of its dd-cfDNA kitted test to the FDA, marking a critical step in the product development process.
GlobeNewswire Inc. · Oct 2, 2024
Oncocyte Corporation announced a $10.2 million private placement of securities, with participation from new and existing investors, including strategic partner Bio-Rad Laboratories. The company plans to use the proceeds for working capital and general corporate purposes.
Investing.com · Jul 5, 2024
Oncocyte Corp held its 2024 Annual Meeting of Shareholders, resulting in the re-election of four directors and the ratification of its independent registered public accounting firm. The company also confirmed the independence of its board chairman.
GlobeNewswire Inc. · Jun 17, 2024
Oncocyte Appoints Seasoned Finance Executive Andrea James as Chief Financial Officer
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OCX.
No results
No recent SID articles mention OCX.
